FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to an HIF-2α-inhibiting pharmaceutical solid dosage form for oral administration of a compound by the formula (I)
Formula (I),
and to methods for treatment including administration of said dosage form. The solid dosage form includes a solid dispersion including a compound by the formula (I) and one or more pharmaceutically acceptable excipients. The solid dispersion therein includes a pharmaceutically acceptable polymer selected from the group consisting of hydroxypropyl methylcellulose acetate (HPMCAS), cellulose acetate phthalate (CAP), and a polyethylene glycol-polyvinyl acetate-polyvinyl caprolactam graft copolymer, and the solid dosage form constitutes a capsule or tablet. Also claimed is a method for treating von Hippel-Lindau disease (VHL) and a method for treating renal cell carcinoma.
EFFECT: invention increases the stability, bioavailability, and quality of storage of the pharmaceutical dosage form.
18 cl, 15 dwg, 33 tbl, 18 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS AND COMPOSITIONS FOR STABILISATION OF HYPOXIA INDUCED FACTOR-2 ALPHA AS METHOD OF CANCER MEDICAL TREATMENT | 2012 |
|
RU2602498C2 |
PHARMACEUTICAL COMPOSITION OF PYRAZOLE COMPOUND DISPERSED IN POLYMER MATRIX | 2020 |
|
RU2826604C1 |
IMPROVED THERAPEUTIC INDEX OF INHIBITORS AGAINST IMMUNE CHECKPOINT USING COMBINATION THERAPY INCLUDING PHY906 EXTRACT, SCUTELLARIA BAICALENSIS GEORGI (S) EXTRACT OR COMPOUND OF SUCH EXTRACTS | 2017 |
|
RU2753523C2 |
CRF1 RECEPTOR ANTAGONIST, PHARMACEUTICAL FORMULATIONS AND SOLID FORMS FOR TREATING CONGENITAL ADRENAL HYPERPLASIA | 2019 |
|
RU2824490C2 |
PHARMACEUTICAL COMPOSITION AND ITS ADMINISTERING | 2013 |
|
RU2802442C2 |
PHARMACEUTICAL COMPOSITION AND INTRODUCTION THEREOF | 2013 |
|
RU2692779C2 |
METHODS FOR INCREASING STABILISATION OF HYPOXYA INDUCED FACTOR-1 ALPHA | 2010 |
|
RU2521251C2 |
METHOD FOR REDUCING MULTI-DRUG RESISTANCE WITH USING INOSITOL TRIPYROPHOSPHATE | 2010 |
|
RU2563127C2 |
NANOPARTICLE, CONTAINING RAPAMYCIN AND ALBUMIN AS ANTI-CANCER AGENT | 2008 |
|
RU2483714C2 |
PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
Authors
Dates
2022-05-24—Published
2019-10-23—Filed